The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.

In this experiment, for vehicle-treated mice, this did not reach statistical significance, although numerically is entirely consistent with earlier published studies that reached significance with larger mouse numbers [ 5 , 7 ] (Fig. 4 A).

also in 111,027 other papers

Overall, 25 genes showed a trend of difference in at least one of the test substrates, and of these, the majority, 18 (72%) were downregulated in TG mice, identified in bold in Fig. 1 A.

also in 53,322 other papers